JP2002512023A - 膀胱癌組織由来ヒト核酸配列 - Google Patents
膀胱癌組織由来ヒト核酸配列Info
- Publication number
- JP2002512023A JP2002512023A JP2000544779A JP2000544779A JP2002512023A JP 2002512023 A JP2002512023 A JP 2002512023A JP 2000544779 A JP2000544779 A JP 2000544779A JP 2000544779 A JP2000544779 A JP 2000544779A JP 2002512023 A JP2002512023 A JP 2002512023A
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- seq
- sequence
- acid sequence
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000007523 nucleic acids Chemical group 0.000 title claims abstract description 102
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 title claims abstract description 16
- 206010005003 Bladder cancer Diseases 0.000 title claims abstract description 15
- 201000005112 urinary bladder cancer Diseases 0.000 title claims abstract description 15
- 108091028043 Nucleic acid sequence Proteins 0.000 title claims description 43
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 98
- 239000002299 complementary DNA Substances 0.000 claims abstract description 60
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 38
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 38
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 20
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 17
- 229920001184 polypeptide Polymers 0.000 claims abstract description 15
- 102000004169 proteins and genes Human genes 0.000 claims description 51
- 230000000692 anti-sense effect Effects 0.000 claims description 29
- 230000014509 gene expression Effects 0.000 claims description 20
- 239000012634 fragment Substances 0.000 claims description 15
- 210000004102 animal cell Anatomy 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 6
- 108020004414 DNA Proteins 0.000 claims description 5
- 230000000295 complement effect Effects 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 239000003623 enhancer Substances 0.000 claims description 4
- 238000002823 phage display Methods 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 3
- 210000005260 human cell Anatomy 0.000 claims description 3
- 210000001236 prokaryotic cell Anatomy 0.000 claims description 3
- 238000012546 transfer Methods 0.000 claims description 3
- 241000588724 Escherichia coli Species 0.000 claims description 2
- 241001465754 Metazoa Species 0.000 claims description 2
- 230000014107 chromosome localization Effects 0.000 claims description 2
- 108020001507 fusion proteins Proteins 0.000 claims description 2
- 102000037865 fusion proteins Human genes 0.000 claims description 2
- 238000001415 gene therapy Methods 0.000 claims description 2
- 230000002068 genetic effect Effects 0.000 claims description 2
- 108020004999 messenger RNA Proteins 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims 1
- 238000007876 drug discovery Methods 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 230000003584 silencer Effects 0.000 claims 1
- 108700026220 vif Genes Proteins 0.000 claims 1
- 210000005253 yeast cell Anatomy 0.000 claims 1
- 108700026244 Open Reading Frames Proteins 0.000 description 51
- 150000001413 amino acids Chemical class 0.000 description 47
- 210000001519 tissue Anatomy 0.000 description 30
- 210000000056 organ Anatomy 0.000 description 26
- 108091060211 Expressed sequence tag Proteins 0.000 description 15
- 238000000034 method Methods 0.000 description 12
- 108091035707 Consensus sequence Proteins 0.000 description 10
- 206010028980 Neoplasm Diseases 0.000 description 9
- 238000013507 mapping Methods 0.000 description 5
- 239000013598 vector Substances 0.000 description 5
- 238000000636 Northern blotting Methods 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 210000000349 chromosome Anatomy 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 108020004635 Complementary DNA Proteins 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 210000005068 bladder tissue Anatomy 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 210000003917 human chromosome Anatomy 0.000 description 2
- 210000004754 hybrid cell Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 230000009452 underexpressoin Effects 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102100033779 Collagen alpha-4(IV) chain Human genes 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 241001635598 Enicostema Species 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 102100036738 Guanine nucleotide-binding protein subunit alpha-11 Human genes 0.000 description 1
- 101000710870 Homo sapiens Collagen alpha-4(IV) chain Proteins 0.000 description 1
- 101000619542 Homo sapiens E3 ubiquitin-protein ligase parkin Proteins 0.000 description 1
- 101100283445 Homo sapiens GNA11 gene Proteins 0.000 description 1
- 101000879758 Homo sapiens Sjoegren syndrome nuclear autoantigen 1 Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 206010064912 Malignant transformation Diseases 0.000 description 1
- 206010027626 Milia Diseases 0.000 description 1
- 101000969137 Mus musculus Metallothionein-1 Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 102100037330 Sjoegren syndrome nuclear autoantigen 1 Human genes 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 238000003340 combinatorial analysis Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000002559 cytogenic effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000012268 genome sequencing Methods 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 101150066555 lacZ gene Proteins 0.000 description 1
- 230000036212 malign transformation Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000031864 metaphase Effects 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 102000045222 parkin Human genes 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 102220240796 rs553605556 Human genes 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19818619.3 | 1998-04-21 | ||
| DE19818619A DE19818619A1 (de) | 1998-04-21 | 1998-04-21 | Menschliche Nukleinsäuresequenzen aus Blase-Tumor |
| PCT/DE1999/001170 WO1999054447A2 (de) | 1998-04-21 | 1999-04-15 | Menschliche nukleinsäuresequenzen aus blasentumorgewebe |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2002512023A true JP2002512023A (ja) | 2002-04-23 |
Family
ID=7865833
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000544779A Pending JP2002512023A (ja) | 1998-04-21 | 1999-04-15 | 膀胱癌組織由来ヒト核酸配列 |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP1073742A2 (de) |
| JP (1) | JP2002512023A (de) |
| DE (1) | DE19818619A1 (de) |
| WO (1) | WO1999054447A2 (de) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6358508B1 (en) | 1997-06-11 | 2002-03-19 | Human Genome Sciences, Inc. | Antibodies to human tumor necrosis factor receptor TR9 |
| AU3316600A (en) | 1999-02-22 | 2000-09-21 | Torben F. Orntoft | Gene expression in bladder tumors |
| US6573364B1 (en) | 1999-03-10 | 2003-06-03 | Curagen Corporation | Isolation and characterization of Hermansky Pudlak Syndrome (HPS) protein complexes and HPS protein-interacting proteins |
| EP1248855A4 (de) * | 1999-09-27 | 2004-12-22 | Quark Biotech Inc | Charakteristische sequenzen für blasenkrebs |
| AU2001264769A1 (en) * | 2000-05-17 | 2001-11-26 | Oregon Health And Sciences University | Induction of apoptosis and cell growth inhibition by protein 4.33 |
| US6974672B2 (en) | 2002-03-19 | 2005-12-13 | Amgen Inc. | Gene amplification in cancer |
| CA2514841A1 (en) * | 2003-02-02 | 2004-08-19 | Palo Alto Institute Of Molecular Medicine | Cell-killing molecules and methods of use thereof |
| DE10309729A1 (de) * | 2003-02-26 | 2004-09-16 | Hinzmann, Bernd, Dr. | Humane Nukleinsäuresequenzen aus Harnblasenkarzinomen |
| JPWO2005093063A1 (ja) * | 2004-03-29 | 2008-02-14 | 株式会社医学生物学研究所 | 固形癌診断キット及び固形癌治療用医薬 |
| EP1961762A1 (de) * | 2007-02-21 | 2008-08-27 | Institut Gustave Roussy | Proteinphosphatase-1/GADD34-Inhibitoren, deren Herstellung und Verwendung |
| JP2010502681A (ja) | 2006-09-08 | 2010-01-28 | アンスティテュ・グスターブ・ルシ | プロテインホスファターゼ１、ｇａｄｄ３４およびプロテインホスファターゼ１／ｇａｄｄ３４複合体の阻害剤、その調製および使用 |
| JP5777340B2 (ja) * | 2007-08-06 | 2015-09-09 | オリオン ゲノミクス エルエルシー | Ｉｇｆ２遺伝子の対立遺伝子特異的な発現を判定するための一塩基多型ならびに新規および公知の多型の組み合わせ |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5382521A (en) * | 1992-07-14 | 1995-01-17 | Michigan Cancer Foundation | Method of determining metastatic potential of bladder tumor cells |
| CA2291260A1 (en) * | 1997-06-06 | 1998-12-10 | Human Genome Sciences, Inc. | 207 human secreted proteins |
-
1998
- 1998-04-21 DE DE19818619A patent/DE19818619A1/de not_active Withdrawn
-
1999
- 1999-04-15 WO PCT/DE1999/001170 patent/WO1999054447A2/de not_active Application Discontinuation
- 1999-04-15 JP JP2000544779A patent/JP2002512023A/ja active Pending
- 1999-04-15 EP EP99927682A patent/EP1073742A2/de not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| WO1999054447A2 (de) | 1999-10-28 |
| DE19818619A1 (de) | 1999-10-28 |
| WO1999054447A3 (de) | 2000-07-06 |
| EP1073742A2 (de) | 2001-02-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002512795A (ja) | 膵臓癌組織由来ヒト核酸配列 | |
| JP2002532055A (ja) | 子宮内膜腫瘍組織からのヒト核酸配列 | |
| Zhang et al. | Cloning and functional analysis of cDNAs with open reading frames for 300 previously undefined genes expressed in CD34+ hematopoietic stem/progenitor cells | |
| EP0705903B2 (de) | Mutationen des mit 17q verbundenen Ovarial- und Brustkrebs Empfindlichkeitsgens | |
| Yoshida et al. | The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene | |
| JP2002511252A (ja) | 卵巣腫瘍組織からのヒト核酸配列 | |
| JP2002506643A (ja) | 乳房腫瘍組織に由来するヒト核酸配列 | |
| US20030194704A1 (en) | Human genome-derived single exon nucleic acid probes useful for gene expression analysis two | |
| JP2001512013A (ja) | 前立腺に発現される分泌タンパク質の５’ｅｓｔ | |
| JP2001512011A (ja) | 組織非特異的分泌タンパク質の５’ｅｓｔ | |
| JP2001512015A (ja) | 脳における分泌タンパク質の５’ｅｓｔ | |
| JP2002511259A (ja) | ５’ｅｓｔおよびコードされるヒトタンパク質 | |
| JP2001512012A (ja) | 精巣およびその他の組織で発現する分泌タンパク質の５’ｅｓｔ | |
| Seroussi et al. | Characterization of the human NIPSNAP1 gene from 22q12: a member of a novel gene family | |
| JP2002531052A (ja) | 正常膀胱組織由来ヒト核酸配列 | |
| JP2002510486A (ja) | 正常卵巣組織からのヒト核酸配列 | |
| JP2001512014A (ja) | 脳組織から同定された分泌タンパク質の５’ｅｓｔ | |
| JP2002536995A (ja) | 結腸の疾患に関連する遺伝子 | |
| JP2002512023A (ja) | 膀胱癌組織由来ヒト核酸配列 | |
| JP2001512005A (ja) | 内胚葉において発現する分泌タンパク質の５’ｅｓｔ | |
| JP2002525024A (ja) | 種々の組織中で発現される分泌タンパク質の５’ｅｓｔ | |
| JP2002512017A (ja) | 正常子宮組織からのヒト核酸配列 | |
| JP2002505877A (ja) | 前立腺腫瘍組織由来のヒト核酸配列 | |
| Allikmets et al. | Characterization and mapping of three new mammalian ATP-binding transporter genes from an EST database | |
| JP2002506639A (ja) | ヒト正常乳房組織からのヒト核酸配列 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20050208 |